Ex vivo reversal of the anticoagulant effects of edoxaban

Thrombosis Research

Volumn 134, Issue 4, 2014, Pages 909-913

  Halim, Abdel Baset ^a,d   Samama, Meyer M ^b,c   Mendell, Jeanne ^a  

^a DAIICHI SANKYO INC   (United States)

^b HÔTEL DIEU   (France)

^c Biomnis   (France)

^d DrugScan   (United States)

Author keywords

Anticoagulant reversal; Edoxaban; EIBA; Factor Xa; rFVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A ANTIBODY; D DIMER; EDOXABAN; PROTEIN ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; PYRIDINE DERIVATIVE; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE;

ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ANTAGONISM; EX VIVO STUDY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; BLOOD CLOTTING; DRUG EFFECTS;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; FACTOR VIIA; HEMOSTATICS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRIDINES; RECOMBINANT PROTEINS; THIAZOLES;

EID: 84908145070     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.07.036     Document Type: Article

References (25)

1. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008;6:1542-9.
2. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
3. The Hokusai-VTE Investigators. Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15.
4. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-53.
5. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013;13:331-42.
6. Akwaa F, Spyropoulos AC. Treatment of bleeding complications when using oral anticoagulants for prevention of strokes. Curr Treat Options Cardio Med 2013;15:288-98.
7. Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 2013;80:443-51.
8. Jackson II LR, Becker RC. Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis 2014;37:380-91.
9. Kazmi RS, Lwaleed BA. New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol 2011;72:593-603.
10. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013;118:1466-74.
11. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87(Suppl. 1):S141-5.
12. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013;106:382-93.
13. Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011;104:669-76.
14. NovoSeven® RT Coagulation Factor VIIa (Recombinant). Full prescribing information. Bagsvaerd, Denmark: Novo Nordisk A/S; 2012 [Available at: http://www.novo-pi.com/novosevenrt.pdf].
15. Moss J, Scharling B, Ezban M, Moller Sorensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost 2009;7:299-305.
16. FEIBA NF. Anti-inhibitor coagulant complex, vapor heated and nonfiltered, freeze-dried substance with solvent for intravenous injection or infusion. Product monograph. Mississauga, ON, Canada: Baxter Corporation; 2014 [Available at: http://www.baxter.ca/en/downloads/product-information/FEIBA-NF-PM-17April2014-EN.pdf].
17. Tjonnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patientswith high-titer inhibitors. Vasc Health Risk Manag 2007;3:527-31.
18. Prothrombin Complex Concentrate (Human), Kcentra™. Full prescribing information. Marburg, Germany: CSL Behring GmbH; 2013 [Available at: www.kcentra.com/prescribing-information.aspx].
19. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012;107:253-9.
20. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62. http://dx.doi.org/10.1016/S0140-6736(13)62343-0.
21. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108:217-24.
22. Snipelisky D, Kusumoto F. Current strategies to minimize the bleeding risk of warfarin. J Blood Med 2013;4:89-99.
23. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012;116:94-102.
24. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013;168:4228-33.
25. Herzog E, Kaspereit F, Krege W, Pragst I, Yoshiyuki M, Dickneite G. Four-factor prothrombin complex concentrate (4-PCC) effectively reverses edoxaban induced bleeding in a rabbit model of acute injury. Blood 2013;122:1133.